Trial · NCT02709889
Participant flow44
How many started, completed or left each group, period by period.
1 to 20 of 44
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part A: Rovalpituzumab Tesirine 0.2 mg/kg | 43 | |
| Overall Study | STARTED | Part A: Rovalpituzumab Tesirine 0.3 mg/kg | 57 | |
| Overall Study | STARTED | Part A: Rovalpituzumab Tesirine 0.4 mg/kg | 12 | |
| Overall Study | STARTED | Part B: Rovalpituzumab Tesirine 0.3 mg/kg | 88 | |
| Overall Study | Large Cell Neuroendocrine Carcinoma(NEC) | Part A: Rovalpituzumab Tesirine 0.2 mg/kg | 3 | |
| Overall Study | Large Cell Neuroendocrine Carcinoma(NEC) | Part A: Rovalpituzumab Tesirine 0.3 mg/kg | 4 | |
| Overall Study | Large Cell Neuroendocrine Carcinoma(NEC) | Part A: Rovalpituzumab Tesirine 0.4 mg/kg | 2 | |
| Overall Study | Large Cell Neuroendocrine Carcinoma(NEC) | Part B: Rovalpituzumab Tesirine 0.3 mg/kg | 4 | |
| Overall Study | Neuroendocrine Prostate Cancer | Part A: Rovalpituzumab Tesirine 0.2 mg/kg | 4 | |
| Overall Study | Neuroendocrine Prostate Cancer | Part A: Rovalpituzumab Tesirine 0.3 mg/kg | 7 | |
| Overall Study | Neuroendocrine Prostate Cancer | Part A: Rovalpituzumab Tesirine 0.4 mg/kg | 3 | |
| Overall Study | Neuroendocrine Prostate Cancer | Part B: Rovalpituzumab Tesirine 0.3 mg/kg | 7 | |
| Overall Study | Gastroenteropancreatic NEC | Part A: Rovalpituzumab Tesirine 0.2 mg/kg | 6 | |
| Overall Study | Gastroenteropancreatic NEC | Part A: Rovalpituzumab Tesirine 0.3 mg/kg | 5 | |
| Overall Study | Gastroenteropancreatic NEC | Part A: Rovalpituzumab Tesirine 0.4 mg/kg | 2 | |
| Overall Study | Gastroenteropancreatic NEC | Part B: Rovalpituzumab Tesirine 0.3 mg/kg | 23 | |
| Overall Study | Other NEC | Part A: Rovalpituzumab Tesirine 0.2 mg/kg | 11 | |
| Overall Study | Other NEC | Part A: Rovalpituzumab Tesirine 0.3 mg/kg | 12 | |
| Overall Study | Other NEC | Part A: Rovalpituzumab Tesirine 0.4 mg/kg | 1 | |
| Overall Study | Other NEC | Part B: Rovalpituzumab Tesirine 0.3 mg/kg | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02709889/flow